{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:53:24Z","timestamp":1780106004347,"version":"3.54.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013591","name":"Alliance Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013591","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100031962","name":"Walgreens Boots Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031962","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EORTC Cancer Research Fund"},{"name":"Fonds Cancer"},{"name":"Walgreen Boots Alliance"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115493","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:10:26Z","timestamp":1747163426000},"page":"115493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8786-0645","authenticated-orcid":false,"given":"Marie","family":"Morfouace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6388","authenticated-orcid":false,"given":"Franck","family":"Bielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-2947","authenticated-orcid":false,"given":"Evangelia","family":"Razis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Estrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-7423","authenticated-orcid":false,"given":"Alba","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8423","authenticated-orcid":false,"given":"Teresa","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1799-3785","authenticated-orcid":false,"given":"Sara","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia Capela","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnana Prakash","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5928-1108","authenticated-orcid":false,"given":"Lionel","family":"D\u2019Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-9806","authenticated-orcid":false,"given":"Johnny","family":"Duerinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Michotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ribalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Marucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-9477","authenticated-orcid":false,"given":"Vassilis","family":"Golfinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5322","authenticated-orcid":false,"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-5141","authenticated-orcid":false,"given":"David TW","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-0707","authenticated-orcid":false,"given":"Martin G.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115493_bib1","unstructured":"Central nervous system tumours: WHO classification of tumours, 5th Edition. IARC Publications; 2021."},{"key":"10.1016\/j.ejca.2025.115493_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib3","unstructured":"ECIS \u2013European Cancer Information System. Estimates of cancer incidence and mortality in 2022, for all countries. European Union."},{"key":"10.1016\/j.ejca.2025.115493_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.115493_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research","year":"2008","journal-title":"Nature"},{"issue":"98-110","key":"10.1016\/j.ejca.2025.115493_bib6","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115493_bib7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm.4204","article-title":"Recurrent MET fusion genes represent a drug target in pediatric glioblastoma","volume":"22","author":"International Cancer Genome Consortium PedBrain Tumor","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115493_bib8","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S1470-2045(14)70113-5","article-title":"Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials","volume":"15","author":"Fern","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/ijc.32651","article-title":"EORTC SPECTA-AYA: a unique molecular profiling platform for adolescents and young adults with cancer in Europe","volume":"147","author":"de Rojas","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2025.115493_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2022.10.020","article-title":"Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: results of the EORTC SPECTA-AYA international proof-of-concept study","volume":"178","author":"Morfouace","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115493_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.009","article-title":"Next-generation personalised medicine for high-risk paediatric cancer patients \u2013 the INFORM pilot study","volume":"65","author":"Worst","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115493_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-023-02255-1","article-title":"Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology","volume":"29","author":"Sturm","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115493_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ng.3036","article-title":"Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications","volume":"46","author":"Rimmer","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115493_bib14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12859-019-2851-0","article-title":"TelomereHunter \u2013 in silico estimation of telomere content and composition from cancer genomes","volume":"20","author":"Feuerbach","year":"2019","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.ejca.2025.115493_bib15","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/2159-8290.CD-21-0094","article-title":"The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets","volume":"11","author":"van Tilburg","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115493_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/neuonc\/noad008","article-title":"EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection","volume":"25","author":"Capper","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib17","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13060","article-title":"The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors","volume":"32","author":"Bale","year":"2022","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ejca.2025.115493_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115493_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00401-018-1879-y","article-title":"Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience","volume":"136","author":"Capper","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115493_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.annpat.2021.11.005","article-title":"The 2021 WHO classification of tumours of the central nervous system","volume":"42","author":"Figarella-Branger","year":"2022","journal-title":"Ann Pathol"},{"key":"10.1016\/j.ejca.2025.115493_bib23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","article-title":"Primary brain tumours in adults","volume":"402","author":"van den Bent","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115493_bib24","article-title":"Mismatch repair deficiency and lynch syndrome among adult patients with glioma","volume":"7","author":"Benusiglio","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/2159-8290.CD-21-1136","article-title":"The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies","volume":"12","author":"Berlanga","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115493_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s43018-022-00474-y","article-title":"The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations","volume":"4","author":"Villani","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2025.115493_bib27","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2022.07.008","article-title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers","volume":"33","author":"Jahn","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib28","first-page":"i44","article-title":"Deciphering the relationship of microsatellite-instability and mutational burden in high-grade glioma patients with constitutionally impaired dna damage response","volume":"367","author":"Blattner-Johnson","year":"2023","journal-title":"SNO Pediatr Conf"},{"key":"10.1016\/j.ejca.2025.115493_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-020-02243-6","article-title":"Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis","volume":"141","author":"Suwala","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115493_bib30","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115493_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/bjs.11902","article-title":"European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender","volume":"108","author":"Seppala","year":"2021","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2025.115493_bib32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","article-title":"Combined immunotherapy improves outcome for replication-repair-deficient (RRD) HIgh-grade Glioma Failing Anti-PD-1 monotherapy: a report from the international RRD consortium","volume":"14","author":"Das","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115493_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","article-title":"Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency","volume":"28","author":"Das","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115493_bib34","article-title":"Immune checkpoint inhibition as single therapy for synchronous cancers exhibiting hypermutation: an IRRDC study","volume":"6","author":"Henderson","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib35","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/PO.21.00153","article-title":"Upfront adjuvant immunotherapy of replication repair-deficient pediatric glioblastoma with chemoradiation-sparing approach","volume":"5","author":"Larkin","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial","volume":"19","author":"Lih","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2025.115493_bib37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.30828","article-title":"Precision oncology based on omics data: The NCT Heidelberg experience","volume":"141","author":"Horak","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2025.115493_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11060-013-1176-5","article-title":"Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series","volume":"114","author":"Chamberlain","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2025.115493_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211040013","article-title":"Durable progression-free survival with the use of BRAF and MEK inhibitors in four cases with BRAF V600E-mutated gliomas","volume":"28","author":"Fusco","year":"2021","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejca.2025.115493_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","article-title":"Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma","volume":"16","author":"Johanns","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejca.2025.115493_bib41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","article-title":"Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor","volume":"175","author":"Hu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.115493_bib42","first-page":"18","article-title":"MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors. Holistic Integrative","volume":"1","author":"Zhang","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2025.115493_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jcpt.12378","article-title":"Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma","volume":"41","author":"Ameratunga","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2025.115493_bib44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1159\/000509773","article-title":"Durable complete response of a recurrent mesencephalic glioblastoma treated with trametinib and low-dose dabrafenib in a patient with neurofibromatosis type 1","volume":"13","author":"Awada","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib45","article-title":"Trametinib in patients with NF1-, GNAQ-, or GNA11-mutant tumors: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols S1 and S2","volume":"7","author":"Wisinski","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00401-022-02478-5","article-title":"Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1","volume":"144","author":"Lucas","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115493_bib47","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.21.02840","article-title":"Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm E of the NCI-COG pediatric MATCH trial","volume":"40","author":"Eckstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115493_bib48","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/2159-8290.CD-20-1050","article-title":"Mutations in the RAS\/MAPK pathway drive replication repair-deficient hypermutated tumors and confer sensitivity to MEK inhibition","volume":"11","author":"Campbell","year":"2021","journal-title":"Cancer Discov"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:30Z","timestamp":1762342530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"alternative-id":["S0959804925002746"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115493","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115493"}}